Pacer Advisors
VKTX icon

Pacer Advisors’s Viking Therapeutics VKTX Stock Holding History

Pacer Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,909
Closed -$101K – 2708
2024
Q2 		$101K Buy
1,909
+1,317
+222% +$86.3K ﹤0.01% 2336
2024
Q1 		$48.5K Buy
+592
New +$26.3K ﹤0.01% 3177
2021
Q2 		– Sell
-8,140
Closed -$51K – 1563
2021
Q1 		$51K Sell
8,140
-232
-3% -$1.63K ﹤0.01% 1435
2020
Q4 		$47K Buy
8,372
+2,597
+45% +$15.7K ﹤0.01% 1421
2020
Q3 		$34K Buy
+5,775
New +$39.8K ﹤0.01% 1324
2018
Q4 		– Sell
-18,994
Closed -$331K – 1028
2018
Q3 		$331K Buy
+18,994
New +$226K 0.01% 937

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Pacer Advisors's VKTX Position: Q3 2024 in Review

Pacer Advisors sold out of Viking Therapeutics (VKTX) in Q3 2024, closing a stake of 1,909 shares — an estimated $101K sold.

Pacer Advisors first reported a position in VKTX in Q3 2018 and held it in 6 quarters. The position peaked at $331K in Q3 2018. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Pacer Advisors reported no remaining Viking Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 1,909 Viking Therapeutics shares in Q3 2024, an estimated $101K.
  • Pacer Advisors first reported a position in Viking Therapeutics in Q3 2018 and held it in 6 quarters.
  • Pacer Advisors's Viking Therapeutics position peaked at $331K in Q3 2018.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.